Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

New Pacific Metals delivers robust Silver Sand pre-feasibility study

Project with post-tax NPV of $740M and IRR of 37% By Francois Kalos New Pacific Metals Corp. ( TSX:NUAG; NYSE-A:NEWP ) has delivered a strong pre-feasibility study (PFS) for its Silver Sand silver project in Potosi, Bolivia. The PFS is consistent with the r...

Why Roth Capital Partners gives GameSquare a 'buy' rating

(Source: Roth Capital Partners) Click here to download Roth Capital Partners’ full report on GameSquare Holdings . This is third-party provided content issued on behalf of GameSquare Holdings Inc. (NDAQ:GAME) , please see full discl...

How This Food Investment Company is Making the Plant-based Sector Accessible

Interest in plant-based products is hotter now more than ever, and companies in this sector are busy ramping up their efforts to meet the demand from consumers as the switch to more sustainable lifestyles continues to grow. Eat Well Investment Group Inc. ( CSE:EWG , ...

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. In a June 16 research note, ROTH Capital Partners analyst Scott Henry reported that Beyond Air Inc. (XAIR:NASDAQ) enrolled the first patient in its U.S. clin...

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...

Why So Many Analysts Have a Buy on This Company on the Cusp of Silver Production

Analysts say MAG Silver offers production as well as exploration upside. Juanicipio mine MAG Silver Corp.'s (MAG:TSX; MAG:NYSE A) joint venture with Fresnillo Plc (FRES:LSE) is gearing up to begin silver production at the high-grade, large-scale...

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report. In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanc...
1 2 3 4 5 6 7 8 9 10